Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 20/20 | 0.68 |
| ▸ | MARK3 | P27448 | 3/20 | 0.63 |
| ▸ | IKBKE | Q14164 | 3/20 | 0.63 |
| ▸ | CDK2 | P24941 | 2/20 | 0.63 |
| ▸ | BRSK2 | Q8IWQ3 | 2/20 | 0.63 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.63 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.63 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.61 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.56 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.56 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.55 |
| ▸ | ULK3 | Q6PHR2 | 1/20 | 0.55 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13431995 | 0.98 | TBK1 (0.65) | TBK1MARK3IKBKECDK2BRSK2 | |
| SCHEMBL13432088 | 0.87 | TBK1 (0.67) | TBK1MARK3IKBKECDK2BRSK2 | |
| SCHEMBL22818572 | 0.87 | STK17B (0.59) | TBK1MARK3IKBKECDK2BRSK2 | |
| SCHEMBL23331347 | 0.85 | TBK1 (0.50) | TBK1MARK3IKBKECDK2BRSK2 | |
| SCHEMBL1284852 | 0.85 | TBK1 (0.61) | TBK1MARK3IKBKECDK2BRSK2 | |
| SCHEMBL22818574 | 0.85 | ULK1 (0.52) | TBK1MARK3IKBKECDK2BRSK2 | |
| SCHEMBL15188869 | 0.85 | TBK1 (0.50) | TBK1MARK3IKBKECDK2BRSK2 | |
| SCHEMBL13431851 | 0.82 | TBK1 (0.76) | TBK1MARK3IKBKECDK2BRSK2 | |
| SCHEMBL22818563 | 0.81 | TBK1 (0.49) | TBK1MARK3IKBKECDK2BRSK2 | |
| SCHEMBL13431907 | 0.81 | TBK1 (1.00) | TBK1MARK3IKBKECDK2BRSK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | LIFEARC (GB) | 2024-06-27 | — | — | US | disclosed |
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | LIFEARC (GB) | 2024-06-27 | — | — | US | disclosed |
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | LIFEARC (GB) | 2024-06-27 | — | — | US | disclosed |
| EP-4320121-A2 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES AS ULK1/2 INHIBITORS AND THEIR USE THEREOF | LifeArc (GB) | 2024-02-14 | — | — | EP | disclosed |
| CN-117545751-A | 2, 4-diaminopyrimidine derivatives as ULK1/2 inhibitors and their use | 生命爱科 | 2024-02-09 | — | — | CN | disclosed |
| US-20230338376-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-10-26 | — | — | US | disclosed |
| US-20230338376-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-10-26 | — | — | US | disclosed |
| US-11590134-B2 | Aminopyrimidine amide autophagy inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| WO-2022214869-A2 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | LIFEARC (GB) | 2022-10-13 | — | — | WO | disclosed |
| US-20210128556-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2021-05-06 | — | — | US | disclosed |
| US-20100056524-A1 | Compound | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-03-04 | — | — | US | disclosed |
| US-20100056524-A1 | Compound | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-03-04 | — | — | US | disclosed |
| WO-2009122180-A1 | PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES | MEDICAL RESEARCH COUNCIL (GB) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056524-A1 | Compound | NR3C2, NR3C1, NR2E3 | TBK1 2898/4885MARK3 1239/4885IKBKE 1433/4885 |
| US-20210128556-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | TBK1 260/4885MARK3 398/4885IKBKE 1382/4885 |
| US-11590134-B2 | Aminopyrimidine amide autophagy inhibitors and methods of use thereof | BECN1, SQSTM1, ATG7 | TBK1 260/4885MARK3 398/4885IKBKE 1382/4885 |
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | ULK1, ULK2, ULK3 | TBK1 38/4885MARK3 253/4885IKBKE 577/4885 |
| US-20230338376-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | TBK1 260/4885MARK3 398/4885IKBKE 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.